Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $56.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target hoisted by Piper Sandler from $44.00 to $56.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. UBS Group upped their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. TD Cowen increased their target price on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Zacks Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $48.15.

Teva Pharmaceutical Industries Trading Up 2.0%

Shares of TEVA stock traded up $0.87 during trading hours on Thursday, hitting $44.52. 7,562,490 shares of the company were exchanged, compared to its average volume of 6,968,955. The firm has a market cap of $51.88 billion, a PE ratio of 103.53, a PEG ratio of 4.09 and a beta of 0.97. Teva Pharmaceutical Industries has a 1 year low of $24.01 and a 1 year high of $44.57. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59. The firm has a fifty day moving average of $40.16 and a 200 day moving average of $35.07.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The business had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. During the same period last year, the company earned $0.78 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $42.91, for a total transaction of $1,072,750.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at $2,392,447.05. The trade was a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Richard Francis sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the sale, the chief executive officer owned 927,529 shares of the company’s stock, valued at approximately $39,178,824.96. This represents a 21.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 715,945 shares of company stock valued at $29,061,351 over the last quarter. 0.54% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. WCM Investment Management LLC boosted its position in Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares during the last quarter. Swiss National Bank increased its position in shares of Teva Pharmaceutical Industries by 28.7% during the first quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock worth $127,344,000 after acquiring an additional 941,700 shares during the last quarter. National Pension Service increased its position in shares of Teva Pharmaceutical Industries by 4.9% during the second quarter. National Pension Service now owns 2,406,013 shares of the company’s stock worth $81,516,000 after acquiring an additional 112,357 shares during the last quarter. Barometer Capital Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth about $2,343,000. Finally, Royal Bank of Canada increased its position in shares of Teva Pharmaceutical Industries by 11.2% during the first quarter. Royal Bank of Canada now owns 963,824 shares of the company’s stock worth $29,030,000 after acquiring an additional 96,938 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Latest Teva Pharmaceutical Industries News

These are some of the TEVA news items that stood out recently:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
• Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.